RBC Bioscience

RBC Bioscience OCF Margin

The Operating Cash Flow Margin of RBC Bioscience (6848.TWO) as of Nov 5, 2026 is 27.25 %. In the previous year, Operating Cash Flow Margin was 7.66 % — a change of 255.82% (higher).

OCF Margin

27.25 %

YoY

255.82%

Last updated:

Operating Cash Flow Margin of RBC Bioscience is 2024 27.25 % . Operating Cash Flow Margin of RBC Bioscience was 2023 7.66 % . It decreases by 255.82% higher compared to the previous year.

The RBC Bioscience OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
3.11 TWD
Jan 1, 2019
24.84 TWD
Jan 1, 2020
35.76 TWD
Jan 1, 2021
-10.07 TWD
Jan 1, 2022
3.80 TWD
Jan 1, 2023
7.66 TWD
Jan 1, 2024
27.25 TWD
The RBC Bioscience OCF Margin history
YEAROCF MarginYoY
27.25 %+255.82%
7.66 %+101.68%
3.80 %-137.70%
-10.07 %-128.17%
35.76 %+43.98%
24.84 %+697.66%
3.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Operating Cash Flow Margin of RBC Bioscience is 27.25 % in 2024.

Operating Cash Flow Margin of RBC Bioscience changed from 7.66 % to 27.25 %, representing a 255.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — RBC Bioscience

All Key Metrics — RBC Bioscience